None DE

Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

['Globenewswire', 'Europe'] FinanzNachrichten.de: News 2026-08-06 00:00:00

Iopofosine I 131, the company's Phospholipid Drug Conjugate (PDC) designed to provide targeted delivery of iodine-131 (radioisotope) Presented data from the CLOVER WaM study of iopofosine I 131 in relapsed/refractory Waldenström macroglobulinemia (r/r WM) patients at the American Society of Clinical Oncology 2026 Annual Meeting (ASCO).

2026 iopofosine million june cellectar phase patients company cancer months

Read Full Article Back to Feed More None